The stock has a 36-month beta value of -2.27. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for KALA is 4.87M, and at present, short sellers hold a 3.27% of that float. On February 13, 2025, the average trading volume of KALA was 47.76K shares.
KALA) stock’s latest price update
Kala Bio Inc (NASDAQ: KALA)’s stock price has dropped by -31.62 in relation to previous closing price of 10.88. Nevertheless, the company has seen a loss of -23.30% in its stock price over the last five trading days. globenewswire.com reported 2025-02-12 that ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) — KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the resignation of Chief Executive Officer (CEO) Mark Iwicki, and the appointment of Todd Bazemore, KALA’s President and Chief Operating Officer, as interim CEO, effective immediately. Mr. Iwicki will continue to serve as Chair of the Board of Directors of KALA following the transition. Mr. Bazemore has served as KALA’s President since December 2021 and as KALA’s Chief Operating Officer since November 2017.
KALA’s Market Performance
Kala Bio Inc (KALA) has seen a -23.30% fall in stock performance for the week, with a 13.59% gain in the past month and a -2.49% plunge in the past quarter. The volatility ratio for the week is 14.31%, and the volatility levels for the past 30 days are at 9.32% for KALA. The simple moving average for the past 20 days is -15.58% for KALA’s stock, with a 12.56% simple moving average for the past 200 days.
Analysts’ Opinion of KALA
Jefferies gave a rating of “Hold” to KALA, setting the target price at $10 in the report published on September 14th of the previous year.
KALA Trading at -0.87% from the 50-Day Moving Average
After a stumble in the market that brought KALA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.57% of loss for the given period.
Volatility was left at 9.32%, however, over the last 30 days, the volatility rate increased by 14.31%, as shares surge +11.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.88% upper at present.
During the last 5 trading sessions, KALA fell by -23.30%, which changed the moving average for the period of 200-days by +20.39% in comparison to the 20-day moving average, which settled at $8.81. In addition, Kala Bio Inc saw 7.20% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KALA starting from Kharabi Darius, who sale 2,021 shares at the price of $7.63 back on Jan 06 ’25. After this action, Kharabi Darius now owns 67,807 shares of Kala Bio Inc, valued at $15,420 using the latest closing price.
Brazzell Romulus K, the of Kala Bio Inc, sale 2,446 shares at $7.63 during a trade that took place back on Jan 06 ’25, which means that Brazzell Romulus K is holding 92,418 shares at $18,663 based on the most recent closing price.
Stock Fundamentals for KALA
Current profitability levels for the company are sitting at:
- -581.53 for the present operating margin
- -1.81 for the gross margin
The net margin for Kala Bio Inc stands at -556.61. The total capital return value is set at -1.35. Equity return is now at value -430.96, with -67.64 for asset returns.
Based on Kala Bio Inc (KALA), the company’s capital structure generated 0.84 points at debt to capital in total, while cash flow to debt ratio is standing at -0.88. The debt to equity ratio resting at 5.4. The interest coverage ratio of the stock is -6.95.
Currently, EBITDA for the company is -36.08 million with net debt to EBITDA at 0.37. When we switch over and look at the enterprise to sales, we see a ratio of 473.65. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.15.
Conclusion
To sum up, Kala Bio Inc (KALA) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
